Biocon’s Malaysia Insulin Plant Wins EU Clearance, Company Is Open To PE Investment
Executive Summary
Biocon has received European regulatory clearance for its new Malaysian insulin plant and also said it is open to private-equity investment proposals for its fast-growing biologics division ahead of a planned IPO.
You may also be interested in...
Biocon Biologics Eyes Sales Of $1bn
Strong growth in Biocon's biologics segment continued in the second quarter and the vertical has now set a target of $1bn in annual sales by the 2021-22 fiscal year.
Biocon Biologics Eyes $1bn In Sales As Q2 Revenues Jump 40%
Strong growth in Biocon's biologics segment continued in the second quarter and the vertical has now set a target of $1bn in annual sales by the 2021-22 fiscal year.
Biocon Pledges To Cut Insulin Prices
India’s Biocon has promised to cut by 50% the cost of recombinant human insulin to 10 cents a day in low- and middle-income nations to help make the life-saving medication “universally accessible.”